For Complement’s CEO, storytelling could be just as critical as data

Dr. Rafiq Hasan has his sights on bringing lessons learned at Bayer to ophthalmology-focused Complement Therapeutics.

By Alexandra Pecci • Feb. 14, 2023

Why are there gaps in mental healthcare? Often it’s flawed trial methodology

Sunovion Pharmaceuticals has developed a more precise way to track symptoms that could be broadly adopted across the industry.

By Kelly Bilodeau • Feb. 10, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Rocket Pharmaceuticals is ready for liftoff in the rare disease space

With two rare disease products on the launch pad for FDA submission in 2023 and a growing pipeline, Rocket is fueled for its next era of growth.

By Taren Grom • Feb. 10, 2023

The unique playbook of Biohaven’s CEO

Vlad Coric’s offbeat business strategy paid off once with a Pfizer buyout. Can he do it again?

By Meagan Parrish • Feb. 8, 2023

Woman of the Week: KaliVir Immunotherapeutics’ Helena Chaye

The triple threat CEO — scientist, lawyer and biotech pro — thinks she’s discovered a key to curing a wide range of cancers.

By Taren Grom • Feb. 8, 2023

Leaps in vax tech — researchers find new ways to tackle old problems like fungal infections and cancer

A growing number of fungal infections has caused a stir in the research community, and new vaccines could be the answer down the road.

By Michael Gibney • Feb. 7, 2023

Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement

Victoria Richon’s latest venture is in the burgeoning field of protein-enhancing drugs that could target a range of diseases.

By Kelly Bilodeau • Feb. 6, 2023

Woman of the Week: Bayer’s Dr. Yesmean Wahdan

The VP of medical affairs and women’s health is focused on an audacious goal to meet the needs of 100 million women globally.

By Taren Grom • Feb. 1, 2023

Astria Therapeutics’ edge in an ultra-rare disease

With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.

By Taren Grom • Feb. 1, 2023

Weight loss drugs: the promise and pitfalls

GLP-1 agonists are dominating the anti-obesity scene — but hurdles remain to their uptake.

By Kelly Bilodeau • Jan. 30, 2023

A biotech CEO’s favorite ‘F’ word

At SFA Therapeutics, patients are the “focus” of Ira Spector’s approach to changing the course of autoimmune disease.

By Taren Grom • Jan. 26, 2023

Gilead’s commercial chief on why 2023 will be a ‘coming out’ year

With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.

By Meagan Parrish • Jan. 26, 2023

Report reveals murky picture of clinical trial diversity gains

Data discrepancies between study phases and indications could provide clues about why some trials have better racial and ethnic diversity than others.

By Alexandra Pecci • Jan. 24, 2023

Already on a roll in oncology, Astellas hunts for big wins in other areas

With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point. 

By Karissa Waddick • Jan. 23, 2023

A Moderna tie-up ushers in new era for CytomX

The antibody-focused company followed up a tough year with big partnerships to keep the ball rolling.

By Michael Gibney • Jan. 18, 2023

Woman of the Week: Genetika+’s Talia Cohen Solal

The CEO is aiming to build a “brain-in-a-dish” to treat all patients for better mental health outcomes.

By Taren Grom • Jan. 18, 2023

Pro sports’ COVID protocols led to real-world data impacts for pharma

After years of pioneering new methods for using data and technology to improve patient health outcomes, IQVIA’s Christina Mack is on the cusp of a research revolution.

By Karissa Waddick • Jan. 16, 2023

Space — the next frontier in drug development

Merck, Bristol Myers Squibb and others are taking small R&D steps in space that could lead to giant leaps for patients.

By Kelly Bilodeau • Jan. 12, 2023

Galecto has identified a master switch to reduce fibroid formation

With expertise surrounding a natural family of proteins and enzymes that can lead to fibrosis, Galecto is exploring the potential to develop cancer treatments.

By Taren Grom • Jan. 11, 2023

Woman of the Week: Form Bio’s Claire Aldridge

The chief strategy officer of Form Bio is harnessing the new company’s computing power and bioinformatics to spur a genomic revolution.

By Taren Grom • Jan. 11, 2023

Chinook Therapeutics nears the finish line in kidney disease

A company focused on kidney disease, Chinook is growing into a commercial outfit as its lead candidate approaches the market.

By Michael Gibney • Jan. 10, 2023

Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck

The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.

By Taren Grom • Jan. 9, 2023

The kindred nature of martial arts and drug development

How the IRLAB Therapeutics CEO is guiding the company in its development of potentially groundbreaking Parkinson’s disease treatments.

By Alexandra Pecci • Jan. 9, 2023

Lilly, Biogen, Eisai brace for Alzheimer’s boom or bust in 2023

As controversies abound and new drugs rise on the regulatory horizon, this year will be big for Alzheimer’s.

By Michael Gibney • Jan. 5, 2023

Woman of the Week: Cambrian BioPharma’s Juliette Han

The CFO and COO is advancing moonshot efforts to address aging-related diseases for the "healthspan" company and is helping emerging biotechs bring innovations out of academia.

By Taren Grom • Jan. 4, 2023